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Abstract
Tissue-specific transcripts are likely to be of importance for the corresponding organ. While attempting to define the
specific transcriptome of the human lung, we identified the transcript of a yet uncharacterized protein, SFTA2. In silico
analyses, biochemical methods, fluorescence imaging and animal challenge experiments were employed to characterize
SFTA2. Human SFTA2 is located on Chr. 6p21.33, a disease-susceptibility locus for diffuse panbronchiolitis. RT-PCR verified
the abundance of SFTA2-specific transcripts in human and mouse lung. SFTA2 is synthesized as a hydrophilic precursor
releasing a 59 amino acid mature peptide after cleavage of an N-terminal secretory signal. SFTA2 has no recognizable
homology to other proteins while orthologues are present in all mammals. SFTA2 is a glycosylated protein and specifically
expressed in nonciliated bronchiolar epithelium and type II pneumocytes. In accordance with other hydrophilic surfactant
proteins, SFTA2 did not colocalize with lamellar bodies but colocalized with golgin97 and clathrin-labelled vesicles,
suggesting a classical secretory pathway for its expression and secretion. In the mouse lung, Sfta2 was significantly
downregulated after induction of an inflammatory reaction by intratracheal lipopolysaccharides paralleling surfactant
proteins B and C but not D. Hyperoxia, however, did not alter SFTA2 mRNA levels. We have characterized SFTA2 and present
it as a novel unique secretory peptide highly expressed in the lung.
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Introduction
A number of lung diseases are likely to be caused by genetic
defects but their pathogenesis is not yet understood. In order to
identify human genes predominantly expressed in the lung, we
screened public databases containing tissue expression profiles. We
identified SFTA2 as a gene specifically expressed in the lung. A
partial mRNA corresponding to the human transcript had been
submitted to NCBI GenBank by M.G. Walker and P. Spiro in
2002 (Accession AY102070) as ‘‘co-expressed with pulmonary
surfactants’’. There is, however, no literature associated with this
finding. The official gene symbol is SFTA2 (‘Surfactant associated
29; HUGO Nomenclature Committee; [1]). Although there is no
published report focusing on SFTA2, Clark et al. [2] predicted
secretion signals for over 1000 proteins from public databases,
SFTA2 being among them. Zhang and Henzel [3] tested the
ability of a computer algorithm to predict cleavage sites of
secretory signals in 270 secreted proteins. For SFTA2 it was found,
that a 19 amino acid signal at the amino terminus was cleaved off
from a precursor. However, as yet there are no published data on
expression or function of SFTA2. Here we present the identifica-
tion of SFTA2 as a gene preferentially expressed in the lung as well
as detailed expression, biochemical and regulation data.
Methods
In Silico Identification and Characterization of SFTA2
Human tissue expression patterns of GEO Profiles (http://
www.ncbi.nlm.nih.gov/geoprofiles) and GeneNote [4] were
screened to identify genes preferentially expressed in the lung
[5]. Homology searches and multiple alignments used BLAST
from the National Center for Biotechnology Information.
Gylcosylation and signal prediction used the NetNGlyc 1.0 and
SignalP 3.0 servers respectively (Technical University of Den-
mark). The PSIPRED Protein Structure Prediction Server
(University College London) and the DiANNA software (identi-
fication of potential disulfide bonds [6]) were also employed.
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Expression Analysis of Normal Tissues by RT-PCR
TissueScanH qPCR cDNA array analysis (Origene, Rockville,
MD, USA) was performed on 48 human tissues using SFTA2-
specific primers according to the manufacturer. The data were
normalized for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) or b-actin. In the mouse, RNA was extracted from 10
normal tissues (lung, liver, heart, kidney, spleen, uterus, cerebrum,
cerebellum, adrenal gland, small intestine), and qPCR-analysis
was performed with normalization for actin on a MastercyclerH ep
realplex (Eppendorf, Hamburg, Germany). Primers used were-
forward: CACACGCAGGGCCAAAGGTG and reverse: GAG-
GAGGCAGATCTTTTGGAG.
In Silico Promoter Analysis
Promoter sequences for SFTA2 homologues from 8 species
(macaca mulatta, pan troglodytes, homo sapiens, mus musculus,
canis lupus familiaris, bos taurus, sus scrofa and equus caballus)
were extracted from the ElDorado database and aligned using
DiAlign [7]. Searches for conserved transcription factor binding
sites and combinations of these (models) were carried out using
FrameWorker (Matrix library 8.3). Common patterns were
required to be present in at least 7 of 8 promoter sequences,
with distances between 10 and 200 bp between neighbouring
binding sites, and with no more than 10 bp distance variation.
ModelInspector was used to scan the SFTA2 promoters for known
functional (published) modules and all human promoter sequences
for newly defined models from SFTA2. DiAlign, FrameWorker
and ModelInspector are part of the Genomatix Software Suite
(www.genomatix.de).
Generation of Expression Constructs
A human SFTA2 cDNA clone (IRATp970H02140D) from
Source BioScience ImaGenes (Berlin, Germany) served to
generate expression plasmids by PCR. The vector pCDNA3.1
(Invitrogen) was used to generate an expression plasmid containing
a C-terminal HA epitope tag (pCDNA-SFTA2-HA). The vector
pMal-c2 (New England Biolabs) was used to generate a construct
for bacterial expression of maltose-binding protein (MBP) fused to
SFTA2 (MBP-SFTA2) excluding the signal sequence. MBP-
SFTA2 was induced and prurified from DH5a E. coli according
to the manufacturer.
Transfection of Human and Mouse Cell Lines and
Immunofluorescence Microscopy
A549 cells (human lung adenocarcinoma) and MLE12 cells
(mouse lung epithelium) were grown to 80% confluence and
transfected using the Amaxa Nucleofector device (Lonza Cologne
GmbH, Cologne, Germany). For immunofluorescence microsco-
py, cells were plated on coverslips, fixed with 3% paraformalde-
hyde for 15 min., permeabilized with 0.15% Triton X-100 for
15 min. and exposed to primary antibodies in a concentration of
1:100. The HA–tag was detected using the high affinity rat
antibody clone 3F10 in a dilution of 1:100 (Roche Diagnostics
Mannheim, Germany). A549 and MLE12 cells have been used
previously to address the issue of subcellular targeting to lamellar
bodies [8,9]. Lamellar bodies were detected by labeling with anti-
LAMP-1 antibodies in A549 cells (clone H4A3) from Development
Studies Hybridoma Bank (Iowa, USA.). In MLE12 cells, we
labelled lamellar bodies by transfection of ABCA3 (ATP binding
cassette subfamily A member 3) cDNA (encoding a lamellar body
lipid transporter) carrying a C-terminal HA-epitope tag. Golgi
bodies were detected using golgin-97 antibody in a dilution of
1:200 (Invitrogen, Life Technologies, Grand Island, U.S.A.).
Clathrin-labelled vesicles were detected by labelling with anti-
Clathrin antibody clone X22 in a dilution of 1:200 (Abcam,
Cambridge, U.K.). Secondary antibodies were compatible goat
anti-species IgG labeled with Alexa fluorophores (Invitrogen,
Carlsbad, USA). 49,6-diamidino-2-phenylindole (DAPI) was used
for counterstaining nuclei. Immunofluorescent cell imaging was
performed with a Zeiss Axiovision 135 inverse fluorescence
microscope.
Generation of Specific Antibodies against Human SFTA2
Three overlapping peptides corresponding to the human
sequence (LKLKESFLTNSSYc, EKLCLLLHLPSGTSc,
SGTSVTLHHARSQHHVc) were coupled to KLH. Two rabbits
were immunized; each with a combination of all three conjugates.
Serum was harvested and tested in ELISA for a specific response
against uncoupled peptides. One rabbit mounted a significant
response against all peptides. This serum was purified against all
three peptides immobilized to a matrix (Primm, Milano, Italy).
Western Blot and Glycosylation Testing
Cell lysates were prepared with RIPA (radioimmunoprecipita-
tion) lysis buffer. Immunoblot analysis followed standard proce-
dures. HA-antibody as above was used in a dilution of 1:1000,
while peptide antibodies were used 1:250 to 1:500. Detection was
achieved by appropriate goat anti IgG antibodies conjugated to
horseradish peroxidase (1:7500) and SuperSignalH West Femto
detection system (Thermo Scientific, Rockford, IL, USA). In order
to test for N-linked glylcosylation we used Endo H on lysates of
cells transfected with pcDNA-SFTA2-HA according to the
manufacturer (New England Biolabs).
Immunostaining of Human Lung Tissue
The use of anonymous human lung tissue was approved by the
ethics committee of the Ludwig-Maximilian University, Munich,
Germany (Reference number: EK 15032011). We were given
permission for use of anonymized lung tissue (left over after clinical
investigations) without consent. Lung tissue had been freshly
collected during bronchoscopy, snap-frozen in liquid nitrogen, and
stored at280uC. For immunostaining, frozen sections (4 mm) were
prepared (Frozen Section Medium Neg-50; Richard-Allan Scien-
tific, MI, USA), fixed with cold acetone for 2 minutes, dried and
then stored at 280uC. After abolishment of endogenous perox-
idase activity (3% H2O2, 15 minutes) sections were treated with
primary antibodies specific for thyroid transcription factor-1,
(TTF-1 1:50; mouse monoclonal 8G7G3/1; Santa Cruz Biotech-
nology, CA, USA) and SFTA2 (1:50; rabbit; purified peptide
antibody) for 60 minutes at room temperature. Detection was
achieved with compatible fluorescein-conjugated secondary Alexa
Fluor antibodies (Invitrogen, CA, USA). Nuclei were counter-
stained with DAPI (05 mg/ml; Sigma-Aldrich, Germany) and
covered with fluorescent mounting medium (DAKO; Glostrup,
Denmark). The preparations were analyzed with a Zeiss Axio
Imager fluorescence microscope (Zeiss; Munich, Germany) and
images were captured with a monochromatic Zeiss Axiocam and
Axiovison software (Version 4.8). Differential interference contrast
microscopy enabled visualization of lung morphology.
Animal Experiments
All animal experiments were performed according to the
Federal Act on the Protection of Animals (Germany) and approved
by the committee of the District Government of Upper Bavaria
(Reference number: 55.2-1-54-2531-24-08). For the lipopolysac-
charide (LPS)-challenge study, fourteen 9–11 week-old female
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C57BL/6 mice were anesthetized by intraperitoneal injection of
Medetomidin, Midazolam and Fentanyl and randomized to
receive an intratracheal instillation of either 1 mg/kg body weight
LPS (LPS O55:B5, Sigma, Munich, Germany) in normal saline
(total volume 80 ml) or 80 ml normal saline. Immediately after
instillation, the lungs were inflated with a Flexivent small animal
ventilator (DMI, Cerritos, CA, USA) to allow for even distribution.
The animals were then kept as usual for 18 h after which they
received an intraperitoneal injection of pentobarbital and were
killed by exsanguination. Following tracheotomy, the lungs were
lavaged twice with 0.6 ml of normal saline and the recovered fluid
was pooled. Then the lungs were removed, snap-frozen in liquid
nitrogen and stored at 280uC.
For the oxygen challenge study, eight 9–11 week-old mice were
randomized to either be kept normally or exposed to 95% oxygen
for 72 hrs. All mice were then anesthetized, lavaged and sacrificed
as above and lung tissue was prepared.
Alveolar Epithelial Cells Isolation
Primary alveolar epithelial type II (ATII) cells were isolated from
mice as previously described [10]. In brief, lungs were lavaged 2x
with 1 ml sterile PBS, tissues digested with dispase and minced. The
suspension was sequentially filtered through 100-, 20-, and 10-mm
nylon meshes and centrifuged at 2006g for 10 min. The pellet was
resuspended in DMEM and a negative selection for lymphocytes/
macrophages was performed by incubation on CD16/32- and
CD45-coated Petri dishes for 30 min at 37uC.Negative selection for
fibroblasts was performed by adherence for 45 min on cell culture
dishes. Cell purity and viability was analysed in freshly isolated ATII
cells directly after isolation. Cell purity was routinely assessed by
epithelial cell morphology and immunofluorescence analysis of
panCK, pro-SPC (both positive), aSMA, and CD45 (both negative)
of cytocentrifuge preparations of ATII cells. Cell viability was
checked by Trypan Blue exclusion. ATII cells used throughout this
study demonstrated a 9563% purity and .97% viability.
RNA Extraction and RT-PCR from Mouse Lung Tissue and
Cell Lines
RNA extraction with RNAzol followed the manufacturer’s
protocol (WAK-Chemie Medical, Steinbach, Germany). RNA
extracted from the above process was further purified using the
RNAeasy protect minikit (Qiagen, Valencia, CA). cDNA was
made using the First strand CDNA synthesis kit (GE healthcare,
Piscataway, NJ). RNA was also extracted from A549, Calu-3 and
HEK-29 cell lines and SFTA2 q-PCR analysis performed with
normalization for GAPDH. Primers used were: SFTA2 -
forward: GGAGTCTTTTCTGACAAATTCCTC and reverse:
GGTGTTGAGATCTTGCATGGTGG.
Real-time PCR from mouse lung tissue was carried out to
determine the effect of different challenges on the levels of type-2
cell specific genes in the lung. The following genes were detected
using the respective primers. SFTA2: Forward - CACACG-
CAGGGCCAAAGG Reverse - GAGGAGGCAGATCTTTTG;
Sp-B: Forward - CACTGAGGATGCCATGGGCC Reverse -
TGATCACAGACTTGCAGAAATGGCACT; Sp-C: Forward -
CTTTCCTGTCCCGCTGCGGTT Reverse -
GGCCTTGCTGTCAGCACCCTG; Sp-D: Forward -
TCCTGGGCATCCTCAAAAGGCT Reverse - AGCGTCTA-
GAGGTTGCCTTCTCCC; Actin: Forward -
GTGGGCCGCCCTAGGCACCA, Reverse –
TGGCCTTAGGGTTCAGGG; HPRT – Forward - ATG
TCC GGT AAC GGC GGC, Reverse - GGT ACA AGG
CTT TCA GCA TCG C.
Statistics
Statistical analyses employing the Mann–Whitney U test were
performed with the software SPSS version 18.0 (Chicago, U.S.).
Results
Gene Characteristics of Human SFTA2
SFTA2 is a single copy gene on chromosome 6 p21.33. It
contains 3 exons with small introns such that the total genomic
region corresponding to the transcript comprises only 826 bp.
Interestingly, this region has been associated with diffuse
panbronchiolitis (DPB) in Japanese patients [11]. SFTA2 is
positioned close to DPCR1, an unconfirmed candidate gene for
DPB, MUC21 (mucin 21), which encodes a mucin highly
expressed in the lung, and PBMUCL1 (panbronchiolitis related
mucin-like 1), polymorphisms of which have been associated with
DPB [12].
Expression of SFTA2 in Human and Mouse Tissues
SFTA2 was identified to be highly expressed in the lung based
on RNA-analysis using chip hybridization methods. In order to
verify this data with an independent method, we investigated 48
human tissues by quantitative RT-PCR. While lung was the
predominant organ, expression was also detected in cervix,
esophagus, stomach, testis and kidney at levels above 1% of that
found in the lung (Table 1). The following tissues or cells expressed
less than 0.1% of the level found in the lung: duodenum, pituitary,
trachea, ureter, adipose tissue, retina, prostate, vena cava,
intracranial artery, placenta, epididymis, ovary, seminal vesicles,
bone marrow, oviduct, tonsil, spinal cord, thymus, penis, colon,
lymphocytes, urinary bladder, heart, optic nerve, small intestine,
skeletal muscle, brain. SFTA2 is expressed in a number of human
lung tumors but also tumors of the breast, ovary and cervix as well
as tumor-derived cell lines (GeoProfiles).
In the mouse, SFTA2 was predominantly expressed in the lung
while all other tissues investigated showed less than 1% of lung
levels (data not shown).
SFTA2 Promoter Characteristics
A scan of promoter regions of SFTA2 orthologues for known
functional modules revealed two interesting combinations. A
V$ETSF-V$SP1 combination ((V$ETSF: ETS1 factors; (EHF,
ELF1through 3, ELF4, ELF5, ELK1, ELK3, ELK4, ERF, ERG,
ETS1, ETS2, ETV1, ETV2, ETV3, ETV4, ETV5, ETV6,
ETV7, FEV, FLI1, GABPA, GABPAP, GABPB1, GABPB2,
SPDEF, SPI1, SPIB, SPIC), V$SP1F: GC-Box factors SP1/GC;
(SP1 through 7; KLF10, KLF11 KLF16 KLF5)) was conserved in
7 species (hsa, mml, ptr, eca, cfa, bta, ssc), which has been reported
to regulate the human Bruton’s agammaglobulinemia tyrosine
kinase (BTK) [13], crucial in B-cell development. The second
combination, V$ETSF-V$NFKB, (V$NFKB: Nuclear factor
kappa B/c-rel (HIVEP1, HIVEP2, HIVEP3, NFKB1, NFKB2,
REL, RELA, RELB) was conserved in 5 species (hsa, ptr, eca, bta,
ssc), and has been identified as an important regulatory element
for IRF8-dependent upregulation of CCL5 as part of the innate
immune response [14]. A highly conserved region of about 80 bp
(identified by DiAlign2 [7]) 300 bp upstream of the human SFTA2
transcription start site contains several potential binding sites for
homeodomain factors, including NKX-2-1 encoding thyroid
transcription factor 1 (TTF-1), which plays an important role in
lung development. These V$NKXH sites (V$NKXH: NKX
homeodomain factors (HMX1, HMX2, HMX3, NKX2-1,
NKX2-2, NKX2-3, NKX2-4, NKX2-5, NKX2-6, NKX2-8,
NKX3-1, NKX3-2) are conserved in all 8 species and, except
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e40011
for sus scrofa, even in modules together with binding sites for Myc
associated zinc fingers (V$MAZF MAZ, PATZ1), C2H2 zinc
finger transcription factors 2 (V$ZF02: ZNF281, ZBTB7B,
ZNF219, ZBTB7A, ZNF148, ZNF202, ZKSCAN3, ZNF300) or
Krueppel-like transcription factors (V$KLFS: KLF1, KLF2,
KLF3, KLF4, KLF6, KLF7, KLF8, KLF9, KLF12, KLF13,
KLF15). All three binding site families have members with a role
in the immune system (PATZ1, KLF6, ZNF148).
In the same region, however, 65 models containing 3 sites were
identified with very specific distances due to the high evolutionary
conversation. These models comprise 16 transcription factor
binding site families. A scan through all human promoters using
ModelInspector revealed a high specificity for transcription factor
combinations with these specific distances. 35 are only present in
the SFTA2 promoter and less than 25 times in the whole human
genome (between 4 and 22 times). The remaining 30 modules are
found in promoters of additional genes (between 2 and 24
depending on the module). Among these are genes involved in
lung development (SHH, GABRA1, GABRA3), lipid metabolism
(LPL, CROT) and immune response (CD69, IL1RAP, BECN1)
but no other surfactant proteins.
SFTA2 Predicted Protein Characteristics
Human SFTA2 is a small peptide. The primary translation
product comprises 78 amino acids. Cleavage of a 19 bp signal
gives rise to a mature peptide of 59 amino acids (predicted
molecular weight 6.55 kDa). SFTA2 is not hydrophobic such as
surfactant proteins B or C.
Orthologues were easily identified in all mammals including
marsupials due to a high degree of conservation (Fig.1).
Chromosomal localizations in syntenic regions confirmed the
identity of orthologues for which chromosomal localizations were
known. No other sequence-related proteins were identified in the
databases. In addition to the signal peptide, two regions showed
particularly high conservation (AA 25–33 and AA 44–66; Fig. 1).
A helical structure could be predicted between AA 44 and 55.
However, no similarity of these regions to known domains shared
by other proteins was recognized.
Potential N-glycosylation signals were identified as depicted in
Fig.1. The signal present in the human sequence at position 37 was
missing in other animals such as pika, mouse or rat. However, all
of these other species showed a glycosylation site at the position
corresponding to the human AA 62 (Fig.1). In the amino acid
sequence alignment of 21 species only 5 amino acid positions were
fully conserved, and this was true for both the cysteine residues
(Fig. 1). This and a prediction by the DiANNA software suggest a
disulfide bond between C51 and C76.
SFTA2 is Located in Intracellular Vesicles but not in
Lamellar Bodies
In immunofluorescence microscopy of cultured SFTA2-HA
transfected cells, we could clearly identify colocalization of the
signal arising from the peptide antibody with the signal arising
from the HA-epitope antibody, indicating that the peptide
antibody recognized the protein arising from transfection
(Fig. 2A). Subcellular localization was in small cytoplasmic
compartments, consistent with secretory vesicles. LAMP1, a
marker of lamellar bodies and lysosome-related organelles, did
not show colocalization with SFTA2 in A549 cells (Fig. 2B).
Furthermore, using ABCA3 as a lamellar body marker in MLE12
cells a pattern distinctly different from lamellar bodies was found
for SFTA2 (Fig. 2C).
SFTA2 Colocalizes with Golgi Apparatus and Secretory
Vesicle Markers
Colocalization experiments in transiently transfected A549 cells
with golgin-97, a marker for Golgi apparatus, anti-clathrin
antibody, a marker for secretory vesicles, and HA-epitope showed
partial colocalisation of HA-antibody with golgin-97 and anti-
clathrin antibody (Fig. 3) indicating that SFTA2 is a secretory
protein and its subcellular localization is consistent with the
classical secretory pathway.
SFTA2 is an N-glycosylated Protein
The predicted molecular weight of SFTA2 is 6.55 kDa. While
our peptide antibody recognized the transfected (Fig. 2A) and
bacterially expressed recombinant protein (Fig. 4A), the affinity for
the antigen in immunoblot analyses was apparently not sufficient
to detect the natural protein in lung and A549 homogenates.
Transfection of MLE12 cells with the SFTA2-HA construct
resulted in specific bands at 13 kDa and 6 kDa, if cells were
harvested after 24 h. After 48 h only the 13 kDa band was
detected (Fig. 4 B, C). This would be consistent with a shift of the
apparent molecular weight (retardation in polyacrylamide gel
electrophoresis) due to glycosylation of the protein. With Endo H
treatment, the 13 kDa band disappeared and only the predicted
band at 6 kDa was detected, which corresponds to the
deglycosylated peptide.
Table 1. Relative SFTA2 mRNA levels in human tissues
normalized to GAPDH.
Tissue
Relative amount of mRNA normalized for
GAPDH
Lung 100
Cervix 12.94
esophagus 12.85
stomach 3.42
Testis 2.02
Kidney 1.12
Rectum 1.02
pancreas 0.81
Vagina 0.50
lymph node 0.35
Uvula 0.34
pericardium 0,27
Thyroid 0.20
Skin 0.19
Liver 0.19
Tongue 0.19
uterine corpus 0.18
adrenal gland 0.15
Spleen 0.15
mammary gland 0.10
Out of 48 tissues investigated, those with mRNA levels above 0.1% of lung are
listed. The relative amount of the lung was set to 100. The lung is the
predominant site of expression, while there is expression .1% of lung also in
cervix, esophagus, stomach, testis, kidney and rectum. Normalization for b-actin
resulted in the same pattern.
doi:10.1371/journal.pone.0040011.t001
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Figure 1. Alignment of SFTA2 amino acid sequences from 21 mammalian species. Secretory and glycosylation signals are recognized in all
species. Shaded amino acid residues indicate a conservation of .70% (black: identical; grey: conserved). All species missing N-glycosylation signal 1
(position 37; pig, pika, mouse rat) have a signal at position 61. While only five amino acid residues are identical in all species (black dots), the only two
cysteine residues are among them (red dots).
doi:10.1371/journal.pone.0040011.g001
Figure 2. Immunofluorescence microscopic analyses in A549 (A, B) and MLE12 (C) cells after transfection with pCDNA-SFTA2-HA.
A. Cells were analyzed with an HA epitope antibody and an SFTA2-specific peptide antibody. Colocalization of HA and SFTA2 signals indicates that
our SFTA2 antibody recognizes human SFTA2 resulting from transfection. The punctate cytoplasmic pattern is consistent with localization in
secretory vesicles. The background signal of non-transfected cells may have resulted from natural SFTA2 expression in A549 cells. B. SFTA2-HA signals
do not colocalize with lysosomes or lysosome-related organelles such as lamellar bodies as indicated by LAMP1 immunostaining. C. In MLE12 cells,
transfection with a plasmid construct encoding the phospholipid transporter ABCA3 labels the outer membrane of lamellar bodies as ring-like
structures while epitope-tagged SFTA2 yields a distinctly different punctate cytoplasmic pattern.
doi:10.1371/journal.pone.0040011.g002
SFTA2: A Novel Lung Peptide
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SFTA2 is Highly Expressed in Type II Pneumocytes and
Nonciliated Bronchiolar Epithelial Cells
In frozen lung sections, immunfluorescence staining of SFTA2
by our peptide antibody detected specific signals in the cytoplasm
of alveolar epithelial cells and bronchiolar cells. When peptide
antibodies were blocked by preabsorption with the peptides used
for immunization in 10-fold molar excess, immunofluorescence
signals were nearly abolished (Fig. S1). In order to define the cell
types, we double-stained human lung tissues with SFTA2 and
TTF-1 specific antibodies. In the alveolar eptihelium, TTF-1
specifically labels nuclei of type II pneumocytes. and nonciliated
epithelial cells of the terminal bronchiolus [15]. As shown in Fig. 5,
cytoplasmic signals corresponding to SFTA2 were exclusively
detected in cells expressing TTF-1 in their nuclei, thus identified as
type II pneumocytes in the alveolus (Fig. 5A) and nonciliated
epithelium in bronchioli (Fig. 5B).
RT-PCR Studies in Isolated Type-II Cells and Cell Lines
SFTA2 expression was found to be 4-fold in isolated type II cells
of the mouse lung as compared to whole lung homogenate. In
addition, among the cell lines investigated, SFTA2 expression was
highest in Calu-3 cells (35.4 fold) as compared to A549 (Fig.6) and
not detected in HEK-29 cells (not shown).
SFTA2 is Downregulated by LPS-induced Inflammation,
but not by Hyperoxia
Since SFTA2 is expressed by the alveolar and nonciliated
bronchiolar epithelium and most likely secreted into the alveolar
space, we had speculated about a role as a messenger involved in
inflammation and defence. In an intratracheal LPS challenge
model of C57BL/6 mice, we observed a clear downregulation of
Sfta2 paralleling other proteins secreted by the type II cells such as
SP-B or SP-C, but not SP-D, indicating that this downregulation
Figure 3. Immunofluorescence microscopic analysis of A549 cells transfected with an HA epitope-tagged SFTA2 expression
plasmid. A. Partial colocalization with golgin97 indicates passage of SFTA2 through the Golgi apparatus. B. Partial colocalization with clathrin
indicates presence of SFTA2 in secretory vesicles consistent with the classical pathway of secretion.
doi:10.1371/journal.pone.0040011.g003
Figure 4. Immunoblot analysis and N-glycosylation testing of human SFTA2. A. Anti-human SFTA2 peptide antibodies detect 50 ng of
SFTA2-MBP fusion protein with an expected molecular weight of 48.5 kDa. B. 24 hrs after transfection with pCDNA3-SFTA2-HA, specific bands are
detected at the expected 6.5 kDa, but also at 13 kDa (+ transfected, - non-transfected MLE12 cells). C. MLE12 cells were harvested 24 h (left) or 48 h
(right) after transfection. While after 24 hrs the 6 kDa band is still present, it has disappeared after 48 h. Deglycosylation using endo-b-N-
acetylglucosaminidase shifts the 13 kDa band to 6 kDa demonstrating that the 13 kDa band represents a N-glycosylated form.
doi:10.1371/journal.pone.0040011.g004
SFTA2: A Novel Lung Peptide
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was not solely due to damage to type II pneumocytes (Fig. 7A).
Hyperoxia for 72 hours showed no such change (Fig. 7B), although
the inflammatory reaction of the lung due to hyperoxia was clearly
demonstrated by lavage analysis (not shown).
Discussion
We have identified SFTA2 as a novel transcript highly expressed
in the lung. In all mammals with available genomes, the encoded
peptide is unique in the sense that there is no homologue within a
species nor are there any recognizable domain structures shared
by other proteins. SFTA2 is a glycosylated hydrophilic surfactant
protein with a cleavable secretory signal at the amino terminus
highly expressed in type II pneumocytes and nonciliated
bronchiolar epithelium. N-glycosylation may be required for
stabilization of the peptide and a disulfide bond appears likely to
be present.
Secretion of SFTA2 into extracellular space was not demon-
strated here. However, the presence of a specific cleavable
secretory signal in SFTA2 sequence as well as its targeting to
cytoplasmic vesicles partially colocalizing with golgin97 and
Figure 5. Frozen section immunofluorescence microscopic analysis of SFTA2 in the human lung. While DAPI stains all nuclei, TTF-1
(thyroid transcription factor-1) antibodies label nuclei of type II pneumocytes and nonciliated bronchiolar epithelial cells only. A. The SFTA2
polyclonal peptide antibody demonstrates cytoplasmic staining localizing to the same cells as TTF-1 in alveoli (indicating SFTA2 expression restricted
to type II pneumocytes in the alveolus). B. SFTA2 signals also colocalize with TTF-1 in nonciliated bronchiolar epithelium. Merge: superimposition of
all exposures including differential interference contrast to visualize tissue morphology.
doi:10.1371/journal.pone.0040011.g005
Figure 6. Quantitative RT-PCR-analysis of SFTA2 mRNA. Relative abundance was set to 1 for lung tissue and A549 cells respectively. A.
Isolated mouse type II cells demonstrated a 3.8 fold enrichment of SFTA2 messenger RNA compared to total lung tissue. B. SFTA2 mRNA is 35.4 times
more abundant in Calu-3 cells than in A549 cells. While A549 human adenocarcinoma cells show some characteristics of Type II cells, Calu-3 is an
airway adenocarcinoma cell line that expresses submucosal gland cell features.
doi:10.1371/journal.pone.0040011.g006
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clathrin indicate the passage SFTA2 through the classical pathway
of secretion. Specific triggers are probably needed for secretion.
The in silico promoter analysis identified several conserved
binding sites within the SFTA2 promoter. Although these are
frequent sites, combinations with the identified distances are rather
rare. Together with the unique amino acid sequence, we regard
this as an indication of unique regulation and function of SFTA2.
It is striking that SFTA2 expression in the lung parallels the
expression of TTF-1. This is consistent with TTF-1 binding sites
identified in the SFTA2 promoter and may indicate that TTF-1
might regulate SFTA2 expression especially in the lung.
Proteins secreted by type II pneumocytes and nonciliated
bronchiolar epitheliummay serve various functions.While the small
hydrophobic proteins SP-B and SP-C are vital for the physical
properties of pulmonary surfactant and thereby lung expansion
[16,17], the hydrophilic proteins SP-A and SP-D confer innate
immunity promoting phagocytosis by macrophages [18]. Further-
more, SP-A is involved in the control of surfactant production and
both SP-A and SP-D have a role in limiting excessive inflammation
[19,20,21]. We have demonstrated that SFTA2 is neither localized
within lysosomal-related organelles nor is its expression restricted to
type II cells. Therefore, it appears unlikely that SFTA2 (like SP-B or
SP-C) is directly involved in the determination of physical properties
of surfactant. Moreover, we show that SFTA2 is differentially
expressed in response to lung inflammation induced by smooth LPS,
whereas no change is observed in a hyperoxiamodel.While alveolar
macrophages play a role in the reaction to LPS, triggering
inflammation, in hyperoxia direct damage to endothelial and type I
cells results in inflammation. Interestingly, SFTA2 - like SP-A [22]
and SP-D [23] - is also expressed in the female genital tract. The
identification of a specific receptor for SFTA2 in certain lung cell
types (and the female genital tract) will add significantly to our
understanding.
SFTA2 defects may be directly involved in human lung disease.
The SFTA2 locus has been implicated in diffuse panbronchiolitis
(DPB). Possible mechanisms are as yet unclear. In the past,
knockout mouse models have significantly contributed to the
understanding of the function of surfactant proteins [24,25,26].
Therefore, further studies may involve targeting of Sfta2 in mice.
In conclusion, we have identified SFTA2 as a novel secretory
protein predominantly expressed by lung type II pneumocytes and
nonciliated bronchiolar cells. While SFTA2 function has not been
directly addressed, preliminary data encourage speculations on a
regulatory role in inflammation and defence.
Supporting Information
Figure S1 Lung frozen section immunofluorescence
analysis. Blocking of peptide antibody with a 10-fold molar
excess of peptides. While in absence of blocking, the SFTA2
antibody led to distinct cytoplasmic staining (please see Fig. 4),
blocking with the peptides used for antibody generation com-
pletely blocked the specific signal. A. Merge of all images. B.
DAPI staining of all nuclei. C. TTF-1 staining labelling nuclei of
type II cells and nonciliated bronchiolar epithelium. D. Signals
from SFTA2 antibody in the presence of blocking peptides are
nearly absent despite high exposure time. E. Differential
interference contrast to demonstrate lung morphology.
(TIFF)
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Figure 7. Analyses of specific mRNA levels in mouse lung in response to challenges by lipopolysaccharide instillation or oxygen
exposure. The mean values of untreated animals were set to 1.0. A. Sfta2 qRT-PCR of mouse lung tissue 18 h after tracheal LPS instillation in relation
to other type II pneumocyte proteins SP-B, SP-C, SP-D. Significant SFTA2 downregulation was observed in LPS-treated mice paralleling SP-B and SP-C,
but not SP-D. B. Analysis of the same transcripts after room air vs. 95% oxygen exposure. We observed alteration of SFTA2 and any of the other
messages despite significant inflammatory reaction (not shown).
doi:10.1371/journal.pone.0040011.g007
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